Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. [electronic resource]
Producer: 20161111Description: 281-6 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adenocarcinoma of Lung
- Adult
- Afatinib
- Aged
- Aged, 80 and over
- Anaplastic Lymphoma Kinase
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Cohort Studies
- Disease-Free Survival
- ErbB Receptors -- genetics
- Europe
- Female
- Humans
- Lapatinib
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Molecular Targeted Therapy -- methods
- Quinazolines -- therapeutic use
- Quinolines -- therapeutic use
- Receptor Protein-Tyrosine Kinases -- genetics
- Receptor, ErbB-2 -- genetics
- Retrospective Studies
- Trastuzumab -- therapeutic use
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.